Payment overview · 2025
General Payments
$77.77
6 reported records · 5 companies
Healthcare provider profile · identity verified
Sultan Ripon, MD
Allopathic & Osteopathic Physicians|Family Medicine · AUBURN, NY · NPI 1033648662
Verified facts
What the public records show
CMS Open Payments records show Sultan Ripon, MD received $77.77 in general payments during 2025 across 6 reported records.
PFIZER INC. accounted for 28.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.93 | 28.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.90 | 21.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.79 | 19.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.50 | 17.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $10.65 | 13.7% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $77.77 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $10.65 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 73 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
119 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
109 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 654 | 191 |
| Losartan Potassium | Losartan Potassium | 298 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 279 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 268 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 72 |
| Gabapentin | Gabapentin | 262 | 60 |
| Lisinopril | Lisinopril | 258 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 219 | 75 |
| Furosemide | Furosemide | 212 | 72 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 204 | 66 |
| Omeprazole | Omeprazole | 173 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 31 |
| Trazodone Hcl | Trazodone Hcl | 141 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 137 | 37 |
| Metformin Hcl | Metformin Hcl | 130 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 123 | 23 |
| Trulicity | Dulaglutide | 119 | 23 |
| Alendronate Sodium | Alendronate Sodium | 118 | 40 |
| Eliquis | Apixaban | 109 | 24 |
| Sertraline Hcl | Sertraline Hcl | 109 | 27 |
| Buspirone Hcl | Buspirone Hcl | 98 | 21 |
| Montelukast Sodium | Montelukast Sodium | 95 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 29 |
| Allopurinol | Allopurinol | 89 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 84 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 30 |
| Alprazolam | Alprazolam | 79 | 21 |
| Ezetimibe | Ezetimibe | 79 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 23 |
| Ozempic | Semaglutide | 78 | 22 |
| Jardiance | Empagliflozin | 73 | 17 |
| Varenicline Tartrate | Varenicline Tartrate | 71 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 66 | 19 |
| Simvastatin | Simvastatin | 64 | 21 |
| Meloxicam | Meloxicam | 59 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | 17 |
| Januvia | Sitagliptin Phosphate | 55 | 14 |
| Carvedilol | Carvedilol | 52 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 12 |
| Tramadol Hcl | Tramadol Hcl | 51 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 20 |
| Baclofen | Baclofen | 50 | suppressed |
| Mirtazapine | Mirtazapine | 50 | 12 |
| Ibuprofen | Ibuprofen | 49 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 12 |
| Famotidine | Famotidine | 48 | 12 |
| Farxiga | Dapagliflozin Propanediol | 46 | 13 |
| Prednisone | Prednisone | 46 | 29 |
| Meclizine Hcl | Meclizine Hcl | 45 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Potassium Chloride | Potassium Chloride | 42 | 14 |
| Pregabalin | Pregabalin | 41 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 33 |
| Glimepiride | Glimepiride | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | 14 |
| Atenolol | Atenolol | 35 | suppressed |
| Topiramate | Topiramate | 35 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 31 | 12 |
| Naproxen | Naproxen | 30 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 20 |
| Lactulose | Lactulose | 29 | suppressed |
| Lidocaine | Lidocaine | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 20 |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Enulose | Lactulose | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 15 | 12 |
| Ursodiol | Ursodiol | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Klor-Con | Potassium Chloride | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $77.77 · 6 records | PFIZER INC. | CAPVAXIVE, ENFLONSIA, GARDASIL 9, JARDIANCE, M-M-R II, MOUNJARO, PAXLOVID, VAXNEUVANCE, VOQUEZNA, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error